Eli Lilly's US$7b Kelonia Deal Reshapes Oncology And Valuation Story [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
Eli Lilly (NYSE:LLY) has agreed to acquire Kelonia Therapeutics in a transaction valued at up to $7 billion. The deal brings Kelonia's in vivo CAR-T gene therapy platform and KLN-1010, a Phase 1 multiple myeloma program, into Lilly's pipeline. The acquisition marks an expansion of Lilly's efforts in oncology and cell-based cancer treatments. Eli Lilly is moving to broaden its focus beyond its well-known GLP-1 portfolio by committing up to $7 billion for Kelonia Therapeutics. With LLY shares at $919.90 and a 5-year return of around 7x, the company is using its scale and balance sheet to pursue a larger role in cancer treatment. For readers tracking company-specific news, this deal adds another pillar to Lilly's story alongside its existing franchises. For investors, the Kelonia acquisition introduces a different type of pipeline exposure, centered on in vivo CAR-T and an early-stage multiple myeloma asset. The integration and clinical progress of this platform may be followed
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly eyes Kelonia in $7B deal with $3.25B to be paid up front before investors could buy in. How to get in early [Yahoo! Finance]Yahoo! Finance
- Eli Lilly Invests Weight-Loss Windfall in Next-Gen Cancer Treatment [Yahoo! Finance]Yahoo! Finance
- Insilico Medicine Announces Industry's First Longevity Board to Accelerate AI-Driven Aging Research for Drug Discovery [TheStreet.com]TheStreet.com
- Eli Lilly: We Haven't Reached Its Peak Yet (Rating Upgrade) [Seeking Alpha]Seeking Alpha
- Eli Lilly (LLY): 3 Reasons We Love This Stock [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 4/20/26 - Form SCHEDULE
- 3/26/26 - Form SCHEDULE
- 3/20/26 - Form DEFA14A
- LLY's page on the SEC website